Skip to main content

Table 1 Clinical characteristics of B-ALL patients

From: Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach – a population-based study

  1─17 yo 18─65 yo All p-Value
Age groups
Number of patients 122 (76.3%) 38 (23.7%) 160 (100%)  
Median age (range) 4 (1–17) 32 (18–65) 5 (1–65)  
Sex:
Male 69 (56.6%) 15 (39.5%) 84 (52.5%) 0.093
Female 53 (43.4%) 23 (60.5%) 76 (47.5%)
Risk group:
SR 72 (59.5%) 7 (18.4%) 79 (49.7%) < 0.001
IR 38 (31.4%) 17 (44.7%) 55 (34.6%)
HR 5 (4.1%) 6 (15.8%) 11 (6.9%)
HR-SCT 3 (2.5%) 5 (13.2%) 8 (5%)
Induction failure 3 (2.5%) 3 (7.9%) 6 (3.8%)
Not risk grouped 1 0 1
Induction:
Prednisolone 113 (92.6%) 30 (78.9%) 143 (89.4%) 0.030
Dexamethasone 9 (7.4%) 8 (21.1%) 17 (10.6%)
WBC (× 109/l):
< 100 113 (92.6%) 30 (78.9%) 143 (89.4%) 0.030
≥ 100 9 (7.4%) 8 (21.1%) 17 (10.6%)
WBC median (range) 14 (1–641) 10.5 (0.9–481.9) 13.5 (0.9–641) 0.672
Hgb (g/l) median (range) 83 (24–140) 90.5 (52–142) 84 (24–142) 0.117
Platelets median (range) 62 (0–457) 37 (5–320) 54.5 (0–457) 0.075
CNS Status:
CNS1 104 (85.2%) 33 (86.8%) 137 (85.6%) 0.281
CNS2 14 (11.5%) 2 (5.3%) 16 (10%)
CNS3 4 (3.3%) 3 (7.9%) 7 (4.4%)
  1. SR Standard risk, IR Intermediate risk, HR High risk, HR-SCT High risk–stem cell transplant groups, WBC White blood cells, HgB Hemoglobin, CNS central nervous system